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ABSTRACT
Objective: To evaluate the adenosine 2a receptor antagonist preladenant as a nondopaminergic
drug for the treatment of Parkinson disease (PD) when given as monotherapy.
Methods: This was a randomized, 26-week, placebo- and active-controlled, parallel-group, multi-
center, double-blind trial conducted in adults diagnosed with PD for ,5 years who were not yet
receiving L-dopa or dopamine agonists. Patients with a Unified Parkinson’s Disease Rating Scale
(UPDRS) part 3 (motor function) score $10 and Hoehn & Yahr score #3 were randomized
1:1:1:1:1 to preladenant 2, 5, or 10 mg twice daily, rasagiline 1 mg (active-control) once daily,
or placebo. The primary endpoint was the change from baseline at week 26 in the sum of UPDRS
parts 2 (activities of daily living) and 3 scores (UPDRS213).
Results: The number of patients treated was 1,007. Neither preladenant nor rasagiline was supe-
rior to placebo after 26 weeks. The differences vs placebo (95% confidence interval) in UP-
DRS213 scores (with a negative difference indicating improvement vs placebo) were
preladenant 2 mg 5 2.60 (0.86, 4.30), preladenant 5 mg 5 1.30 (20.41, 2.94), preladenant
10 mg 5 0.40 (21.29, 2.11), and rasagiline 1 mg 5 0.30 (21.35, 2.03). Post hoc analyses did
not identify a single causal factor that could explain the finding of a failed trial. Preladenant was
generally well-tolerated with few patients discontinuing due to adverse events (preladenant 7%,
rasagiline 3%, placebo 4%).
Conclusions: No evidence supporting the efficacy of preladenant as monotherapy was observed in
this phase 3 trial. The lack of efficacy of the active control rasagiline makes it difficult to interpret
the results.
Clinical trial registration: Clinicaltrials.gov: NCT01155479.
Classification of evidence: This study provides Class I evidence that for patients with early PD,
preladenant is not effective as monotherapy at the doses studied (2, 5, 10 mg). Neurology®
2017;88:2198–2206
GLOSSARY
AST 5 aspartate aminotransferase; CI 5 confidence interval; DSM-IV 5 Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition; PD 5 Parkinson disease; OR 5 odds ratio; ULN 5 upper limit of normal; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.
The adenosine 2a (A2A) receptor is a nondopaminergic target for the treatment of Parkinson
disease (PD).1–3 Selective A2A receptor antagonists such as istradefylline and tozadenant have
been assessed for efficacy as adjunct treatment to levodopa in patients with moderate to
severe PD with mixed findings.4–9 To date, only istradefylline is approved for treating PD,
and only in Japan. Preladenant is an investigational potent selective A2A receptor antago-
nist.10,11 In a phase 2b trial evaluating preladenant as an adjunct to L-dopa in patients with
fluctuating PD, the drug provided a significant reduction in off time compared to placebo.12
These findings were not confirmed in 2 subsequent phase 3 trials, but the failure of an active
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control, rasagiline, that was included in one
of the trials makes it difficult to interpret the
results.13
Selective A2A receptor antagonists adminis-
tered by themselves have been shown to
improve motor disability in rodent and non-
human primate experimental models of PD,
suggesting that they could be effective when
used as monotherapy in patients with early
PD.10,11,14,15 The only adequately sized mono-
therapy trial of a selective A2A receptor antag-
onist to date did not find a significant effect of
istradefylline over 12 weeks on motor function
compared with placebo, although there was
a numerical improvement.16 Here we report
the results of a trial of preladenant given as
monotherapy in patients with early PD. Rasa-
giline, an MAO-B inhibitor with established
efficacy as monotherapy, was used as an active
control.17,18 The primary objective of the trial
was to demonstrate efficacy of preladenant
over placebo.
METHODS Participants. Participants were enrolled at 153
sites in the Americas, Europe, South Africa, India, and Turkey
from October 2010 to August 2013. Eligible participants were
adults diagnosed with idiopathic PD according to the UK PD
Society Brain Bank criteria,19 and confirmed by the presence of
at least 2 of the cardinal signs (bradykinesia, muscular rigidity,
and resting tremor). If resting tremor was not present, rigidity or
bradykinesia had to be asymmetric; furthermore, a diagnosis
based solely on bradykinesia and postural instability was consid-
ered insufficient. Participants had disease severity no greater than
Hoehn & Yahr stage 3 and Unified Parkinson’s Disease Rating
Scale (UPDRS) part 3 (motor function) score of $10 at screen-
ing.20 Key exclusion criteria included drug-induced or atypical
parkinsonism, prior surgery for PD, cognitive impairment
(Montreal Cognitive Assessment score ,22),21 untreated major
depressive disorder (DSM-IV criteria22 or a Beck Depression
Inventory II score $19),23 impulse control disorders, hallucina-
tions, and other significant conditions that could interfere with
assessments or participation (e.g., psychotic disorder, stroke, and
head injury). Eligible participants had not taken L-dopa or
dopamine agonists for 30 days or more. Participants receiving
anticholinergics or amantadine at a stable dosage for at least the 5
weeks immediately prior to screening were eligible. Those who
had taken MAO inhibitors, including rasagiline, within 30 days
prior to randomization were not eligible.
Design and study treatment. This was a randomized, double-
blind, parallel-group, multicenter trial, conducted in 2 parts of 26
weeks each. In part 1, participants were randomized 1:1:1:1:1 to
preladenant 2, 5, or 10 mg twice daily, rasagiline 1 mg (active-
control) once daily, or placebo. The primary research question
was whether preladenant compared with placebo improves
activities of daily living plus motor function in patients with early
PD. In part 2, participants treated with placebo in part 1 were
switched to preladenant 5 mg twice daily while the others re-
mained on their part 1 treatment; the placebo/preladenant group
was intended as a delayed start group for exploratory efficacy
comparison to the 5 mg preladenant/preladenant group to assess
potential disease-modifying effects if efficacy was demonstrated in
part 1.
During the trial, initiation of PD treatments beyond those
used at baseline was strongly discouraged. However, if a partici-
pant developed an urgent need during the trial, PD treatments
(amantadine, anticholinergics, dopaminergic therapy) could be
prescribed.
Participants were assigned to treatment using a computer-
generated randomized allocation schedule prepared by Merck
and implemented through an interactive voice response system.
Randomization was stratified by history of L-dopa/dopamine ago-
nist use (none vs,30 days). Investigators, site staff, participants,
and monitoring staff remained blinded to treatment allocation
throughout the trials.
Standard protocol approvals, registrations, and patient
consents. The trial was conducted in accordance with princi-
ples of Good Clinical Practice, and was approved by appropri-
ate institutional review boards and regulatory agencies. All
participants provided written informed consent. This trial is
registered in clinicaltrials.gov NCT01155479, Merck Pro-
tocol MK-3814-024.
Assessments. Participants were examined at screening, baseline
(day 1 prior to randomization), and 2, 4, 8, 16, and 26 weeks
after randomization. At each examination, the investigator rated
the participants with the UPDRS20 including mental function
(part 1), activities of daily living (part 2), motor function (part
3), and complications of therapy (part 4). The person adminis-
tering the UPDRS was experienced in its use and underwent
further training and testing for the trial. As far as possible, the
UPDRS was administered by the same experienced qualified rater
for a given participant across clinic visits.
Safety was assessed by review of adverse events (AEs), labora-
tory values, vital signs, and ECGs in all participants who took
treatment. Hepatic function was a particular focus since elevated
liver function tests (alanine aminotransferase [ALT] and aspartate
aminotransferase [AST]) were observed in previous preladenant
studies at higher doses than evaluated here.
Statistical analysis. The primary outcome was change from
baseline in the sum of UPDRS parts 2 and 3 scores (UPDRS213).
This endpoint has been used in several de novo trials with dopa-
mine agonists.24,25 The primary hypothesis was that at least prel-
adenant 10 mg is superior to placebo as measured by the change
from baseline to week 26 in UPDRS213. The primary efficacy
endpoint was analyzed using a constrained longitudinal data anal-
ysis approach with treatment, time, treatment-by-time interac-
tion, strata, and participant effects in the model. The least squares
mean response and pairwise differences between preladenant
doses and placebo, along with 95% confidence intervals (CI), are
reported. A comparison of rasagiline vs placebo was performed
using the same model. The efficacy population (full analysis set)
consisted of all randomized participants with baseline data and
postrandomization endpoint data subsequent to$1 dose of study
medication.
It was planned that approximately 1,000 participants (200
per treatment arm) would be randomized. Results from the
TEMPO trial showed that rasagiline improved UPDRS213 scores
by approximately 3.5 points over placebo with a pooled standard
deviation of 7.2 points.26 Based on a literature review of recent
clinical trials studying the same primary endpoint, the estimated
SD was expected to be 9 points. Using a SD of 9 points and
a 2-sided a5 0.05, 200 participants in each arm provided at least
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91% power to detect a clinically relevant difference of 3 points in
UPDRS213 scores between preladenant and placebo.
Key secondary endpoints were the proportion of respond-
ers (proportion of participants with at least a 20% improve-
ment in UPDRS213 from baseline at week 26) and change
from baseline to week 26 in the UPDRS part 2 (UPDRS2)
score. Responder rates for each treatment arm are presented
along with odds ratios (ORs) and 95% CIs for the ORs com-
paring preladenant dose groups with placebo. The change
from baseline in the UPDRS2 score was evaluated using the
primary endpoint model.
Multiplicity for the preladenant vs placebo comparisons was
controlled using an ordered testing procedure (see e-Methods at
Neurology.org).
Post hoc investigations. Once efficacy results of part 1 of the
trial were known, a number of post hoc investigations were
undertaken. The potential effect of caffeine consumption at base-
line was evaluated by adding a caffeine term to the primary anal-
ysis model. Caffeine is a nonspecific adenosine receptor
antagonist that has been speculated to have a protective effect
in PD.14,27 Results were also analyzed according to geographic
area, as this was found to have an influence on efficacy in a prel-
adenant adjunct trial.13
Classification of evidence. This study provides Class I evi-
dence that for patients with early PD, preladenant is not effective
as monotherapy at the doses studied (2, 5, 10 mg).
RESULTS Participants. Of 1,022 participants ran-
domized, 1,007 were treated and 868 (86% of those
treated) completed part 1 with discontinuations being
similar across treatment groups (figure 1). Part 2 of
the trial was terminated early after the results of part 1
were available and 2 phase 3 adjunctive treatment
trials13 failed to demonstrate superiority of preladen-
ant over placebo (figure e-1).
Baseline characteristics were similar among treat-
ment groups (table 1). Approximately a third of par-
ticipants in each treatment group took concomitant
PD medications (table 1). Of the PD medications
used, 53% were amantadine, 27% were anticholiner-
gics, 8% were dopamine agonists, 6% were L-dopa,
and 7% were other types.
Efficacy. In part 1, neither preladenant nor rasagiline
was superior to placebo in improving UPDRS213
change from baseline score at week 26 (table 2).
Although there was a dose response for preladenant
at all timepoints on the primary endpoint, and the
efficacy of preladenant 10 mg appeared similar to
rasagiline, the placebo arm had the highest improve-
ment and therefore treatment differences vs placebo
were not significant (figure 2). The secondary end-
points of the proportion of responders and UPDRS2
change from baseline score at week 26 also showed no
significant differences between preladenant or rasagi-
line vs placebo (table 2). Due to the failure of prel-
adenant in part 1 and the early termination of part 2
of the trial, no efficacy analyses were performed for
part 2.
Safety. A summary of AEs during part 1 is shown in
table e-1. AEs were reported by around 54%–59%
of participants treated with preladenant and 52% of
participants treated with either rasagiline or
Figure 1 Patient disposition for part 1 (first 26 weeks)
*Fewer than the number treated due to missing postbaseline data.
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placebo. Relatively few participants discontinued
due to AEs (preladenant 4%–10%, rasagiline 3%,
placebo 4%).The most common AE with preladen-
ant was headache (4%–7% vs 3% for placebo) and
the most common AE with rasagiline was dizziness
(5% vs 5% for placebo). One death was reported
during part 1; a participant in the preladenant 10
mg group had a hemorrhagic vascular stroke, which
was considered by the investigator to be unlikely to
be related to study drug.
A summary of AEs during part 2 is shown in table
e-2. During part 2, around 68% of participants re-
ported AEs across treatment arms, higher than in part
1 of the study. There were no striking differences
between treatment groups. The most common AE
with preladenant was headache (6%–10%) and the
most common AE with rasagiline was dizziness (9%).
One death was reported during part 2; a participant
in the preladenant 10 mg group died from a sudden
cardiac event, which was considered by the investiga-
tor to be unlikely to be related to study drug.
In part 1, ALT increases .3 3 the upper limit of
normal (ULN) were preladenant 2 mg 5 1.0% (2/
194), 5 mg5 1.5% (3/198), 10 mg5 4.6% (9/196),
placebo 5 0% (0/193), and rasagiline 5 1.5% (3/
195). In part 2, rates were more similar in the prel-
adenant and rasagiline arms: preladenant 2 mg 5
1.2% (2/165), 5 mg 5 1.2% (2/173), 10 mg 5
3.0% (5/164), placebo/preladenant 5 mg 5 0.6%
(1/175), and rasagiline 5 2.3% (4/181). AST results
were similar overall, but with a lower incidence of
values . 3 3 ULN in both parts of the study. No
Hy’s Law cases were observed (a marker for clinical
significance: ALT 3 3 ULN, alkaline phosphatase
.2 3 ULN, and associated with an increase in bil-
irubin $2 3 ULN).28
Post hoc efficacy analyses. Review of baseline partici-
pant characteristics did not reveal any notable differ-
ences between this and previous monotherapy trials
(table e-3). There was a suggestion that baseline caf-
feine use was associated with UPDRS213 change
from baseline score, with .1 cup/d being associated
with a significantly lower score than #1 cup/d, p 5
0.035. The association was not significant for $1
cup/d vs ,1 cup/d, p 5 0.532. Only a third of
participants reported consuming .1 cup of caffeine
per day (table 1).
Table 1 Baseline characteristics of randomized participants
Preladenant
2 mg BID (n 5 204)
Preladenant
5 mg BID (n 5 204)
Preladenant
10 mg BID (n 5 206)
Placebo
(n 5 204)
Rasagiline
1 mg QD (n 5 204)
Mean (SD) age, y 63.0 (10.5) 62.3 (10.2) 63.8 (11.1) 63.3 (10.0) 62.9 (10.2)
Male, n (%) 126 (62) 114 (56) 116 (56) 122 (60) 119 (58)
White, n (%) 173 (85) 171 (84) 174 (84) 169 (83) 170 (83)
PD duration, y
Mean (SD) 1.0 (1.2) 1.1 (1.2) 1.0 (1.1) 1.0 (1.2) 0.9 (1.2)
Median (range) 0.4 (0.0–5.0) 0.5 (0.0–5.0) 0.4 (0.0–4.6) 0.4 (0.0–4.7) 0.3 (0.0–4.9)
Hoehn & Yahr score, n (%)
1 36 (18) 42 (21) 37 (18) 45 (22) 49 (24)
1.5 31 (15) 31 (15) 40 (19) 31 (15) 30 (15)
2 90 (44) 106 (52) 89 (43) 97 (48) 70 (34)
2.5 27 (13) 16 (8) 29 (14) 25 (12) 31 (15)
3 20 (10) 9 (4) 11 (5) 6 (3) 24 (12)
Caffeine use, n (%)
None 59 (29) 59 (29) 70 (34) 77 (38) 56 (27)
>None–1 cup/glass per day 68 (33) 69 (34) 77 (37) 57 (28) 70 (34)
>1 cup/glass per day 74 (36) 74 (36) 57 (28) 66 (32) 70 (34)
Prior use of L-dopa, n (%) 19 (9) 15 (7) 16 (8) 6 (3) 14 (7)
Concomitant PD medication, n (%)a 72 (36) 74 (37) 63 (31) 78 (39) 74 (36)
Mean (SD) total UPDRS scoreb 29.8 (11.3) 29.1 (12.0) 29.4 (10.8) 29.8 (12.0) 29.7 (13.0)
Mean (SD) UPDRS213 scoreb 28.7 (10.9) 28.1 (11.7) 28.3 (10.4) 28.6 (11.6) 28.5 (12.5)
Mean (SE) UPDRS2 scoreb 7.1 (3.7) 7.0 (3.6) 7.4 (3.6) 7.4 (4.0) 7.2 (3.9)
Abbreviations: PD 5 Parkinson disease; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
a Based on treated participants; figure 1 for sample sizes.
bBased on full analysis set; table 2 for sample sizes.
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Analyses of potential regional differences on
UPDRS213 change from baseline score found that
Latin America and Eastern Europe had the strongest
placebo response whereas the rasagiline response was
strongest in North America and the European Union
(table 3). In a subgroup analysis by region, North
Table 2 Key efficacy results at week 26 (full analysis set)
Efficacy parameter
Estimated response
Preladenant
2 mg BID (n 5 195)
Preladenant
5 mg BID (n 5 202)
Preladenant
10 mg BID (n 5 200)
Placebo
(n 5 195)
Rasagiline
1 mg QD (n 5 195)
Primary: UPDRS213 score
Change from baseline 0.30 21.00 21.80 22.20 21.90
Difference vs placebo (95% CI) 2.60 (0.86 to 4.30) 1.30 (20.41 to 2.94) 0.40 (21.29 to 2.11) — 0.30 (21.35 to 2.03)
p Value 0.003 0.14 0.64 — 0.69
Secondary: Percent responders
(‡20% improvement in UPDRS213 score)
Change from baseline, % 25.9 29.5 31.5 35.2 33.1
Difference vs placebo (95% CI)a 29.7 (221.0 to 1.82) 26.3 (217.6 to 5.05) 23.7 (215.2 to 7.99) — 22.3 (213.9 to 9.24)
p Valueb 0.08 0.27 0.48 — 0.68
Secondary: UPDRS2 score
Change from baseline 0.30 0.10 20.20 20.40 20.20
Difference vs placebo (95% CI) 0.70 (0.09 to 1.27) 0.50 (20.11 to 1.04) 0.20 (20.42 to 0.75) — 0.10 (20.45 to 0.70)
p Value 0.024 0.11 0.58 — 0.67
Abbreviations: CI 5 confidence interval; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
N represents the number of randomized and treated participants with at least 1 postbaseline value.
a Based on Miettinen and Numinen method using model-based adjusted effective sample size.
bp Value is for the estimated odds ratio based on a generalized linear mixed model with baseline average UPDRS213 as a covariate, treatment by time
interaction as fixed effect, and participant as random effect.
Figure 2 Primary endpoint (change from baseline in Unified Parkinson’s Disease Rating Scale (UPDRS)213
score over time)
Estimated mean 6 SE by treatment group; full analysis set. PBO 5 placebo; PRL 5 preladenant; RAS 5 rasagiline.
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America 1 European Union 1 India and Turkey
showed results that were consistent with expectations
of improvement for preladenant 10 mg and rasagiline
vs placebo (figure e-2A) whereas neither preladenant
10 mg nor rasagiline differed from placebo in the
Latin America 1 Eastern Europe subgroup (figure
e-2B). Comparing across figures e-2A and e-2B, it
can be seen that the absolute values for preladenant
10 mg and rasagiline were similar across the 2 regional
subgroups while there was a striking difference in
placebo response.
DISCUSSION The A2a receptor antagonist prela-
denant when given as monotherapy in patients with
early PD did not significantly improve UPDRS
activities of daily living plus motor function scores
compared to placebo. However, because the active
control, rasagiline, also failed to demonstrate a sig-
nificant improvement in UPDRS scores, it is not
possible to determine whether these findings indi-
cate inefficacy for preladenant or are related to is-
sues of study conduct. The only other adequately
sized monotherapy trial of a selective A2A receptor
antagonist to date also failed to demonstrate a sig-
nificant effect of istradefylline.16
Despite these discouraging results, it would be
premature to conclude that A2a receptor antagonists
do not have efficacy as monotherapy. It is possible
that problems with the execution of clinical trials have
hindered our ability to demonstrate efficacy. This is
supported by the failure of rasagiline in our study.
Rasagiline improved UPDRS in 2 previous large
monotherapy trials (TEMPO and ADAGIO)26,29
and its clinical efficacy is supported by other studies
and observations.17,18
There are a number of difficulties in conducting
large trials in de novo parkinsonian patients. Struc-
tural error (inappropriate study design, entry criteria,
endpoints) or operational error (errors in diagnosis,
inappropriate investigators, inadequate training with
inconsistent evaluations, and aberrant or missing
data) can lead to failure of a study. The present study
used a placebo-controlled, active-comparator design
that was similar to previous de novo trials, and the
entry criteria as well as endpoints were similar to other
de novo trials. It is possible that the relatively high
chance of receiving active treatment in our trial of
80%, compared with, for example, 67% in the
TEMPO trial26 and 50% in the ADAGIO trial,29
may have contributed to the high placebo response.
Errors in diagnosis may occur in patients with
early PD. Usually about 15% of participants
enrolled in an early trial are eventually determined
to have other diseases. The problem is further
exacerbated in phase 3 trials, when more sites and
participants are required than for smaller investiga-
tional trials, which can be performed at a few expert
centers. However, this was also the case in studies
with other treatments that found positive results.
Moreover, we took steps to try to ensure accuracy
of diagnosis (for example, a diagnosis based solely
on bradykinesia and postural instability was consid-
ered insufficient) and special attention was paid to
accurate diagnosis during the investigators meeting
and with subsequent follow-up. Nevertheless,
because of the large number of sites required for
Table 3 Post hoc analysis: differences in UPDRS213 score at week 26 by region (full analysis set)
Model estimate
Eastern Europe
(n 5 284)
Latin America
(n 5 228)
India and
Turkey (n 5 73)
European
Union (n 5 240)
North America
(n 5 162)
Baseline mean UPDRS213 score 30.1 29.7 27.1 25.1 29.5
Change from baseline to week 26
Preladenant 2 mg BID 0.9 20.8 21.9 0.6 1.8
Preladenant 5 mg BID 20.8 23.8 0.0 20.1 0.7
Preladenant 10 mg BID 21.9 23.5 23.0 20.7 21.8
Rasagiline 1 mg QD 20.2 24.2 22.5 22.3 20.8
Placebo 24.4a 23.8a 22.1 0.1 0.7
Pairwise comparisons
Preladenant 2 mg BID vs placebo 5.3 3.0 0.2 0.6 1.1
Preladenant 5 mg BID vs placebo 3.6 0.0 2.1 20.1 0.1
Preladenant 10 mg BID vs placebo 2.5 0.3 20.9 20.8 22.4
Rasagiline 1 mg QD vs placebo 4.2 20.3 20.4 22.4b 21.5b
Abbreviation: UPDRS 5 Unified Parkinson’s Disease Rating Scale.
South Africa was excluded from the analysis due to the small number of randomized participants (n 5 3).
aStrongest placebo response.
bStrongest rasagiline response.
Neurology 88 June 6, 2017 2203
ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
the trial, some less experienced investigators may
have been selected, leading to an increase in wrong
diagnosis and inaccurate evaluations.
Another potential issue relates to the measures
used to assess outcomes (UPDRS in this case). Assess-
ments should be performed in a standardized manner
by experienced raters to minimize variability. For this
trial, a comprehensive UPDRS rater training and
qualification program was utilized so all reasonable
steps were taken. Although the UPDRS in not very
sensitive in mildly affected patients, particularly with
regard to early motor deficits, it was able to detect
treatment benefits vs placebo in previous de novo
trials.
An interesting finding emerged in our post hoc
analyses of regional differences. We identified
a large placebo effect in Latin America and Eastern
Europe with numerically greater improvement in
UPDRS scores in these regions in the placebo than
the preladenant or rasagiline groups. The reason for
this finding is not known but a large placebo
response was also observed in a phase 3 adjunct trial
of preladenant in Latin America and Eastern Europe
compared to North America and the European
Union.13 Differences could potentially be due to
clinical trials experience, cultural or language differ-
ences, genetic variation, or as yet unidentified rea-
sons. In those regions in the present monotherapy
trial where the placebo response was lowest (North
America and the European Union), the rasagiline
treatment difference vs placebo of 21.5 to 22.4
points was directionally in line with expectations,
although still less than the 23.5 points the study
was powered to detect and that has been proposed
as a minimal clinically important change.30 Further-
more, in those regions with lowest placebo response,
preladenant showed a dose response in efficacy,
with the highest 10 mg dose having similar efficacy
to rasagiline (differences from placebo of 20.8 to
22.4 for preladenant 10 mg).
Another difficulty in interpreting the results from
monotherapy trials is whether the appropriate doses
were selected for evaluation. The doses of preladenant
were chosen based on those used in the phase 2b
adjunct study in patients with moderate to severe
PD on L-dopa, which demonstrated that 5 and 10
mg were effective. There was no prior experience of
preladenant in patients with early PD who were not
receiving dopaminergic therapy to guide dose selec-
tion. History with many dopaminergic agents sug-
gests that treatment doses for early disease are
similar to adjunct therapy in patients with moderate
to severe PD. However, it is possible that this might
not be true for A2A receptor antagonists.
Preladenant was generally well-tolerated in this
trial, although the highest dose was associated with
more AEs and discontinuations due to AEs than
either placebo or rasagiline. Preladenant showed an
increase in the percentage of patients with ALT in-
creases but no Hy’s Law cases, a marker for clinical
significance,28 were observed. The increase in AEs
and ALT with preladenant, particularly the highest
10 mg dose, suggests that it was having biological
activity despite the failure to demonstrate efficacy.
Our trial did not provide evidence that preladen-
ant is effective as monotherapy in patients with early
PD. The lack of efficacy on the primary endpoint of
the active control, rasagiline, makes it difficult to
interpret these results. Post hoc analyses suggest the
possibility that some aspect of trial administration
may have masked a potential drug effect. Definitive
conclusions regarding the potential efficacy of prela-
denant specifically, and A2a receptor antagonists as
a class, as monotherapy in PD cannot be reached
on the basis of this trial.
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